A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
The overall aim of this study is to determine if epigenetic priming with a DNA methyltransferase inhibitor (DMTi) prior to chemotherapy blocks is tolerable and carries evidence of a clinical efficacy signal as determined by minimal residual disease (MRD), event-free survival (EFS), and overall survival (OS). Tolerability for each of the agents, as well as total reduction in DNA methylation and outcome assessments will be done to simultaneously obtain preliminary biological and clinical data for each DMTi in parallel.
PRIMARY OBJECTIVES:
- Evaluate the tolerability of five days of epigenetic priming with azacitidine and decitabine as a single agent DMTi prior to standard AML chemotherapy blocks.
- Evaluate the change in genome-wide methylation burden induced by five days of epigenetic priming and the association of post-priming genome-wide methylation burden with event-free survival among pediatric AML patients.
SECONDARY OBJECTIVES
- Describe minimal residual disease levels following Induction I chemotherapy in patients that receive DMTi.
- Estimate the event-free survival and overall survival of patients receiving a DMTi prior to chemotherapy courses.
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: Mitoxantrone
- Drug: Idarubicin
- Drug: Daunorubicin
- Drug: Etoposide
- Drug: Azacitidine
- Drug: Cytarabine
- Combination product: ITMHA
- Drug: Fludarabine
- Drug: G-CSF
- Drug: Dexrazoxane
- Drug: Decitabine
- Drug: Sorafenib
- Drug: Erwinia asparaginase
- Drug: Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
- Biological: Stem Cell Transplant
Detailed Description
To determine tolerability, priming with DMTi (azacitidine or decitabine) will be limited to Induction I and II during Part 1 of the study. If DMTi treatment is tolerated during Part 1, the investigators will go on to an Expansion Phase (Part 2) that includes DMTi priming prior to all chemotherapy blocks.
Treatment will consist of 5 blocks of conventional chemotherapy: Induction I, Induction II, Intensification I, Intensification II, and Intensification III over approximately 5 months.
RANDOMIZATION: Patients will be randomized to receive one of two DMTi (azacitidine or decitabine) for 5 days prior to Induction I. Intrathecal (ITHMA) treatments will be given right before treatment on this study or on Day 1 of Induction I treatment. Leucovorin will be given 24-30 hours following ITHMA.
INDUCTION I CHEMOTHERAPY: Patients receive cytarabine, daunorubicin, and etoposide.
INDUCTION II CHEMOTHERAPY; Patients receive their assigned DMTi for 5 days followed by fludarabine, cytarabine, G-CSF, and idarubicin.
Patients are then evaluated and assigned to either the low-risk arm, intermediate-risk arm, or the high-risk arm for Intensification therapy.
Patients with ≥ 5% blasts following Induction II will be considered refractory and will go off therapy. The rare high risk patient with an MRD < 0.1% following Induction I may proceed directly to stem cell transplant (SCT) after Induction II - if a suitable donor is available and the transplant can be performed without delay. MDS patients may proceed to SCT once they have achieved MRD <0.1% irrespective of the number of chemotherapy courses received.
INTENSIFICATION I CHEMOTHERAPY - LOW-RISK AML, INTERMEDIATE-RISK AML, and HIGH-RISK AML with no donor: Patients receive cytarabine and etoposide. After administration of 5 days of a DMTi prior to Inductions I and II satisfies a tolerability determination criterion, patients will also receive their randomly assigned DMTi for five days prior to cytarabine and etoposide.
INTENSIFICATION II CHEMOTHERAPY - LOW RISK AML, INTERMEDIATE-RISK AML, and HIGH-RISK AML with no donor: Patients receive mitoxantrone and cytarabine. After administration of 5 days of a DMTi prior to Inductions I and II satisfies a tolerability determination criterion, patients will also receive their randomly assigned DMTi for five days prior to mitoxantrone and cytarabine.
INTENSIFICATION I CHEMOTHERAPY - HIGH-RISK AML with a donor: Patients receive mitoxantrone and cytarabine followed by stem cell transplant (SCT). Treatment related AML patients and patients with treatment related MDS who have a donor but are not able to receive a SCT without delay will proceed to HR Intensification III and receive erwinia asparaginase and cytarabine. After administration of 5 days of a DMTi prior to earlier courses satisfies a tolerability criterion, patients will also receive their randomly assigned DMTi for five days prior to mitoxantrone and cytarabine or erwinia asparaginase and cytarabine.
Treatment related AML patients and treatment related MDS patients that are not able to receive a SCT should go off treatment following Intensification II.
INTENSIFICATION III CHEMOTHERAPY - INTERMEDIATE-RISK AML and HIGH-RISK AML with no donor: Patients receive erwinia asparaginase and cytarabine. After administration of 5 days of a DMTi prior to earlier courses satisfies a tolerability criterion, patients will also receive their randomly assigned DMTi for five days prior to erwinia asparaginase and cytarabine.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Madera, California, United States, 93636
- Children's Hospital of Central California
-
Orange, California, United States, 92968
- Children's Hospital of Orange County
-
Palo Alto, California, United States, 94304
- Lucile Packard Children's Hospital Stanford University
-
San Diego, California, United States, 92123
- Rady Children's Hospital and Health Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Children's Hospital (Comer)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Children's Hospital of Michigan
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57117
- Sanford Children's Specialty Clinic
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Cook Children's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA:
Diagnostic criteria: Patients must have one of the following diagnoses:
- Acute myeloid leukemia fulfilling the criteria of the WHO Classification (see Appendix I), or
- >5% but < 20% marrow myeloblasts and evidence of a clonal de novo AML genetic abnormality [e.g., t(8;21), inv(16), t(9;11)], or
- Myeloid sarcoma (also referred to as extramedullary myeloid tumor, granulocytic sarcoma, or chloroma), with or without evidence of a leukemia process in the bone marrow or peripheral blood, with confirmation of myeloid differentiation, or
- High grade myelodysplastic syndrome (MDS) with greater than 5% blasts, or
- Patients with treatment related myeloid neoplasms including AML and MDS, provided their cumulative anthracycline dose has not exceeded 230 mg/m2 doxorubicin equivalents.
Other criteria - Patients must meet all the following criteria:
- Age > 28 days and < 22 years at time of study entry inclusive, and
- No prior therapy for this malignancy except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one week or less for hyperleukocytosis), and
- Written informed consent according to institutional guidelines, and
- Female patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to enrollment, and
- Male and female participants of reproductive potential must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.
EXCLUSION CRITERIA:
- Down syndrome
- Acute promyelocytic leukemia (APL)
- BCR-ABL1 chronic myeloid leukemia in blast crisis (CML-BC)
- Juvenile myelomonocytic leukemia (JMML)
- Fanconi anemia (FA)
- Kostmann syndrome
- Shwachman syndrome
- Other bone marrow failure syndromes or low grade (<5% bone marrow blasts) MDS.
- Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
- Use of investigational agents within 30 days or any anticancer therapy for this malignancy within 2 weeks before study entry with the exception of IT therapy, hydroxyurea, or low-dose cytarabine as specified in the protocol document. The patient must have recovered from all acute toxicities from any previous therapy.
- Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
- Pregnant or lactating.
- Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
- Prior chemotherapy, with the exception of hydroxyurea or low-dose cytarabine as specified in the protocol document. The patient must have recovered from all acute toxicities from any previous therapy.
- Patients with treatment related myeloid neoplasms with cumulative anthracyclines greater than 230 mg/m2 doxorubicin equivalents.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: AZA+ADE | AZA+FLAG+Ida | AE | MA
Part 1 Tolerability with AZA - Low Risk Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive low-risk intensifications I & II without azacitidine. Interventions: azacitidine, cytarabine, daunorubicin, etoposide,dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone., ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
|
|
Experimental: DAC+ADE | DAC+FLAG+Ida | AE | MA
Part 1 Tolerability with DAC - Low Risk Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive low-risk Intensifications I & II without decitabine. Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Administered intravenously (IV) over approximately one hour.
Other Names:
|
|
Experimental: AZA+ADE | AZA+FLAG+Ida+Sor | AZA+AE+Sor | AZA+MA+Sor
Part 2 Dose Expansion with AZA - Low Risk Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and low- risk Intensifications I & II. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy. Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Given PO.
Other Names:
|
|
Experimental: DAC+ADE | DAC+FLAG+Ida+Sor | DAC+AE+Sor|DAC+MA+Sor
Part 2 Dose Expansion with DAC - Low Risk Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and low-risk Intensifications I & II. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy. Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Administered intravenously (IV) over approximately one hour.
Other Names:
Given PO.
Other Names:
|
|
Experimental: AZA+ADE | AZA+FLAG+Ida | AE | MA | Asp+AraC
Part 1 Tolerability with AZA - Intermediate Risk Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and then receive intermediate risk Intensifications I, II & III without azacitidine. Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA, |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
|
|
Experimental: DAC+ADE | DAC+FLAG+Ida | AE | MA | Asp+AraC
Part 1 Tolerability with DAC - Intermediate Risk Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive intermediate-risk Intensifications I, II & III without decitabine. Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, erwinia asparaginase, ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Administered intravenously (IV) over approximately one hour.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
|
|
Experimental: AZA| +ADE | +FLAG+Ida+Sor| +AE+Sor| +MA+Sor| +Asp+AraC+Sor
Part 2 Dose Expansion with AZA - Intermediate-Risk Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and intermediate-risk Intensification I, II, and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy. Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Given PO.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
May be used in the event of an Erwinia asparaginase shortage.
Given intramuscularly (IM).
Other Names:
|
|
Experimental: DAC|+ADE | +FLAG+Ida+Sor | +AE+Sor | +MA+Sor | +Asp+AraC+Sor
Part 2 Dose Expansion with DAC - Intermediate-Risk Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and intermediate-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy. Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Administered intravenously (IV) over approximately one hour.
Other Names:
Given PO.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
May be used in the event of an Erwinia asparaginase shortage.
Given intramuscularly (IM).
Other Names:
|
|
Experimental: AZA+ADE | AZA+FLAG-Ida+Sor | AE | MA+Sor | Asp+AraC+Sor
Part 1 Tolerability with AZA - High Risk (no donor) Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I & II and high-risk intensifications I, II & III without azacitidine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations. Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Given PO.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
|
|
Experimental: DAC+ADE | DAC+FLAG+Ida+Sor | AE | MA+Sor | Asp+AraC+Sor
Part 1 Tolerability with DAC - High Risk (no donor) Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I, II & III without decitabine. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations. Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Administered intravenously (IV) over approximately one hour.
Other Names:
Given PO.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
|
|
Experimental: AZA | + ADE | +FLAG+Ida+Sor| +AE+Sor | +MA+Sor | +Asp+AraC+Sor
Part 2 Dose Expansion with AZA - High Risk (no donor) Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy. Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Given PO.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
May be used in the event of an Erwinia asparaginase shortage.
Given intramuscularly (IM).
Other Names:
|
|
Experimental: DAC |+ADE |+FLAG+Ida+Sor |+AE+Sor|+MA+Sor|+Asp+AraC+Sor
Part 2 Dose Expansion with DAC - High Risk (no donor) Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I, II and III. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy. Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, sorafenib, mitoxantrone, erwinia asparaginase, asparaginase erwinia chrysanthemi (recombinant)-rywn, ITMHA. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Administered intravenously (IV) over approximately one hour.
Other Names:
Given PO.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
May be used in the event of an Erwinia asparaginase shortage.
Given intramuscularly (IM).
Other Names:
|
|
Experimental: AZA+ADE | AZA+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor
Part 1 Tolerability with AZA- High Risk (with donor) Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I Induction II and high-risk Intensifications I or high risk intensification III without azacitidine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations. Interventions: azacitidine cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Given PO.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
The transplant protocol will depend on the patient's donor and transplant physician's preference.
Other Names:
|
|
Experimental: DAC+ADE | DAC+FLAG+Ida+Sor | MA+Sor | Asp+AraC+Sor
Part 1 Tolerability with DAC - High Risk (with donor) Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and then receive high-risk Intensifications I or high risk intensification III without decitabine. Patients will proceed to stem cell transplant. Sorafenib is limited to patients with FLT3-ITD+/NUP98-NSD1+ or FLT3-ITD+/WT1mut somatic mutations. Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Administered intravenously (IV) over approximately one hour.
Other Names:
Given PO.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
The transplant protocol will depend on the patient's donor and transplant physician's preference.
Other Names:
|
|
Experimental: DAC |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor
Part 2 Dose Expansion with DAC - High Risk (with donor) Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I & II and high-risk Intensifications I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, DAC will be limited to the first two courses of Induction chemotherapy. They will not receive DAC with Intensification therapy. Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G- CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Administered intravenously (IV) over approximately one hour.
Other Names:
Given PO.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
The transplant protocol will depend on the patient's donor and transplant physician's preference.
Other Names:
|
|
Experimental: AZA |+ADE|+FLAG+Ida+Sor|+MA+Sor|+Asp+AraC+Sor
Part 2 Dose Expansion with AZA - High Risk (with donor) Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I & II and high-risk Intensification I or high risk intensification III. Patients will proceed to stem cell transplant. Sorafenib will be given to patients with FLT3-ITD. For these patients, AZA will be limited to the first two courses of Induction chemotherapy. They will not receive AZA with Intensification therapy. Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, sorafenib, ITMHA, erwinia asparaginase, stem cell transplant. |
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Given IV.
Other Names:
Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
Other Names:
Given IV or intrathecally (IT).
Other Names:
Given IT.
Other Names:
Given IV over approximately 30 minutes.
Other Names:
Given IV.
Other Names:
Given IV immediately before idarubicin administration.
Other Names:
Given PO.
Other Names:
Given IV or intramuscularly (IM).
Other Names:
The transplant protocol will depend on the patient's donor and transplant physician's preference.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of evaluable patients who tolerate five days of single agent DMTi before a standard chemotherapy combination
Time Frame: From enrollment to completion of chemotherapy (up to 8 months after start of therapy)
|
Patients will be monitored for grade 4-5 non-hematologic toxic events during these two courses of chemotherapy.
Tolerating a course is defined as completing the course without experiencing death or a grade 4 non-hematologic toxicity.
|
From enrollment to completion of chemotherapy (up to 8 months after start of therapy)
|
|
Change in genome-wide methylation burden of leukemia cells from diagnosis to after five days of single agent DMTi
Time Frame: From diagnosis to completion of five days of single agent DMTi (up to 2 weeks after start of therapy)
|
Leukemic cells will be collected from patients at diagnosis and after five days of single agent DMTi.
Each sample of leukemic cells will be profiled with a methylation microarray.
For each leukemic sample, genome-wide methylation burden (GWMB) will be computed as the sum of methylation values across all markers.
For each patient, the change in GWMB will be computed as the day 5 GWMB minus the diagnostic GWMB.
|
From diagnosis to completion of five days of single agent DMTi (up to 2 weeks after start of therapy)
|
|
Cox model hazard ratio for association of event-free survival with genome-wide methylation burden
Time Frame: From diagnosis to the first of the following events: death, relapse, resistant disease, second malignancy, or last follow-up (up to 3 years after completion of therapy)
|
Patients will be monitored for the events of interest from enrollment for at least three years.
EFS will be defined as the time elapsed from enrollment to the first of the following events: death, relapse, resistant disease, or second malignancy.
EFS times for subjects who have not experienced these events at the time of analysis will be censored at date of last follow-up.
A Cox regression model will be used to evaluate the association of EFS with genome-wide methylation burden observed after completion of five days of single agent decitabine or azacitidine as randomly assigned.
|
From diagnosis to the first of the following events: death, relapse, resistant disease, second malignancy, or last follow-up (up to 3 years after completion of therapy)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of MRD-evaluable subjects with detectable minimal residual disease after receiving five days of a single agent DMTi followed by araC+daunorubicin+etoposide.
Time Frame: MRD will be measured after completion of DMTi+araC+daunorubicin+etoposide (up to 6 weeks after the start of therapy)
|
Flow cytometry will be used to measure minimal residual disease at diagnosis and after completion of the first course of chemotherapy.
|
MRD will be measured after completion of DMTi+araC+daunorubicin+etoposide (up to 6 weeks after the start of therapy)
|
|
Kaplan-Meier estimate of event-free survival
Time Frame: From diagnosis to the first of the following events: death, relapse, resistant disease, second malignancy, or last follow-up (up to 3 years after completion of therapy)
|
Patients will be monitored for the events of interest from enrollment for at least three years.
EFS will be defined as the time elapsed from enrollment to the first of the following events: death, relapse, resistant disease, or second malignancy.
EFS times for subjects who have not experienced these events at the time of analysis will be censored at date of last follow-up.
|
From diagnosis to the first of the following events: death, relapse, resistant disease, second malignancy, or last follow-up (up to 3 years after completion of therapy)
|
|
Kaplan-Meier estimate of overall survival
Time Frame: From diagnosis to the first of the following events: death or last follow-up (up to 3 years after completion of therapy)
|
Patients will be monitored for death from enrollment for at least three years.
Overall survival will be defined as the time elapsed from enrollment to death.
OS times for subjects who are living at the time of analysis will be censored at date of last follow-up.
|
From diagnosis to the first of the following events: death or last follow-up (up to 3 years after completion of therapy)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jeffrey E. Rubnitz, MD, PhD, St. Jude Children's Research Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myelodysplastic Syndromes
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antimitotic Agents
- Mitosis Modulators
- Protective Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Cardiotonic Agents
- Dermatologic Agents
- Protein Kinase Inhibitors
- Antibiotics, Antineoplastic
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Etoposide
- Etoposide phosphate
- Decitabine
- Sorafenib
- Azacitidine
- Fludarabine
- Cytarabine
- Methotrexate
- Daunorubicin
- Asparaginase
- Idarubicin
- Mitoxantrone
- Hydrocortisone
- Dexrazoxane
- Razoxane
- Asparaginase erwinia chrysanthemi, recombinant-rywn
Other Study ID Numbers
- AML16
- NCI-2017-00928 (Registry Identifier: NCI Clinical Trial Registration Program)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Mitoxantrone
-
PD Dr. Andrew ChanUnknown
-
Institute of Hematology & Blood Diseases Hospital...CSPC Ouyi Pharmaceutical Co., Ltd.Active, not recruiting
-
Huijing WuBeijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical GroupRecruitingAngioimmunoblastic T-cell LymphomaChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingPeripheral T Cell LymphomaChina
-
Hui ZengCSPC Ouyi Pharmaceutical Co., Ltd.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Withdrawn
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Hope Cancer Institute, Inc.UnknownProstate CancerUnited States
-
Lederle LaboratoriesCompletedHIV Infections | Sarcoma, KaposiUnited States
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedAdvanced Gastric CarcinomaChina